Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Hyperlipidemia in nephrotic syndrome].

J G Heaf1

  • 1Nefrologisk afdeling P, Rigshospitalet, København.

Ugeskrift for Laeger
|August 26, 1991
PubMed
Summary

Hyperlipidemia is common in nephrotic syndrome patients, likely due to increased liver fat production. Statins effectively treat this high cholesterol, potentially reducing cardiovascular risks and kidney complications.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Analytical solution of phosphate kinetics for hemodialysis.

Journal of mathematical biology·2023
Same author

Effect of far infrared therapy on arteriovenous fistula maturation, survival and stenosis in hemodialysis patients, a randomized, controlled clinical trial: the FAITH on fistula trial.

BMC nephrology·2021
Same author

Mortality due to bleeding, myocardial infarction and stroke in dialysis patients.

Journal of thrombosis and haemostasis : JTH·2018
Same author

Senescence rates in patients with end-stage renal disease: a critical appraisal of the Gompertz model.

Aging cell·2010
Same author

Vitamin D, surface electromyography and physical function in uraemic patients.

Nephron. Clinical practice·2010
Same author

Algorithm for optimal dialysis access timing.

Clinical nephrology·2007

Area of Science:

  • Nephrology
  • Cardiology
  • Biochemistry

Context:

  • Nephrotic syndrome frequently presents with hyperlipidemia.
  • Hyperlipidemia in this condition may stem from increased hepatic lipogenesis secondary to hypoalbuminemia.
  • Cardiovascular risks are elevated in nephrotic syndrome patients, excluding minimal change disease.

Purpose:

  • To explore the causes and consequences of hyperlipidemia in nephrotic syndrome.
  • To investigate the potential role of hypercholesterolemia in glomerulosclerosis.
  • To highlight effective treatment options for hyperlipidemia in nephrotic syndrome.

Summary:

  • Hyperlipidemia is a common comorbidity in nephrotic syndrome, primarily attributed to increased hepatic lipogenesis.
  • The relationship between hypercholesterolemia, cardiovascular complications, and glomerulosclerosis in nephrotic syndrome requires further elucidation.
  • HMG coenzyme A reductase inhibitors offer an effective therapeutic strategy for managing hypercholesterolemia in these patients.

Impact:

  • Understanding the link between hyperlipidemia and nephrotic syndrome complications can guide clinical management.
  • Effective treatment of hyperlipidemia may mitigate cardiovascular morbidity and mortality associated with nephrotic syndrome.
  • Targeting hypercholesterolemia could potentially slow the progression of glomerulosclerosis in nephrotic patients.

Related Experiment Videos